**Statistics Report – Doping Control 2024**

*Testing per Sport*

During 2024 a total of 161 samples (including blood samples) were collected under IBSA as Testing and Results Management Authority within sone IBSA sports with the higher doping risk scores on IBSA 2024 Risk Assessment, taking also into account the number of practicing athletes and the number of sanctioned events:

|  |
| --- |
| Doping Control - Statistics  |
| Sports |
| Bowling | Football\* | Goalball |
| 4 | 15 | 13 |
| Judo | Powerlifting | Showdown |
| 75 | 9 | 5 |
| TOTAL |
| 161 |

Testing per Gender

Upon IBSA prevails gender parity within its sports, Doping control in 2024 registered as well both genders tested out of competition and in competition at many IBSA Sanctioned events.

|  |
| --- |
| Doping Control - Statistics  |
| Gender |
| Female | Male | Unknow |
| 43 | 77 | 1 |
| TOTAL |
| 161 |

IBSA 2024 Testing Pool (TP) included as well both genders athletes who were tested out of competition and IBSA Antidoping Committee works in tight cooperation with the different IBSA Sports Committees to update the Registered Testing Pool (RTP) for the year 2024.

*Testing per Analysis*

During 2024, IBSA samples were urine at 90% – and 10% of blood samples were collected under IBSA Testing Authority.

The 161 samples were subject to different antidoping analysis menus depending on:

* type of test whether it is IN or OUT of competition
* type of sport discipline in compliance with the TDSSA (Technical Document for Sport Specific Analysis)

|  |
| --- |
| Doping Control - Statistics  |
| Moment |
| In-Competition | Out-of- Competition |
| 89 | 32 |
| *80%* | *20%* |
| TOTAL |
| 161 |

|  |
| --- |
| Doping Control - Statistics  |
| Type of Sample |
| Blood | Urine |
| 16 | 105 |
| *10%* | *90%* |
| TOTAL |
| 161 |

With joint efforts of many stakeholders including not only IBSA but also the National Anti-Doping Organizations (NADOs) and the Local Organizing Committees (LOCs), IBSA samples met almost in all planned sports the MLA (Minimum Level for Analysis) in regard with the compulsory Specific Analysis on urine mainly ERAs (Erythropoietin Recombinant Agents) and GHRFs (Growth Hormone Releasing Factors).

Testing via Cooperation

IBSA 2024 samples were analyzed at 13 different WADA-accredited laboratories to reveal 0 (zero) Possible Adverse Analytical Findings (AAFs) and 2 Atypical Findings (ATFs) which results management is currently ongoing.

To achieve IBSA Testing Plan for 2024, IBSA relied on the services of 15 National Anti-Doping Organizations (NADOs) from 4 continents in addition to 1 private service providers. IBSA Antidoping acknowledges the cooperation of the LOCs who made substantial efforts to meet the requested testing scale in competition.

TUE in 2024

On 2024 we had received the total of 10 requests of TUE, but 2 of them were not Granted so we didn’t process as TUE. We received with a balance between male and female athletes but not in perspective with the sports.

|  |
| --- |
| TUE - Statistics  |
| Gender |
| Female | Male |
| 4 | 6 |
| TOTAL |
| 10 |

|  |
| --- |
| TUE - Statistics  |
| Status |
| Approved | Denied |
| 8 | 2 |
| TOTAL |
| 10 |

|  |
| --- |
| TUE - Statistics  |
| Sports |
| Judo | Football | Goalball |
| 6 | 0 | 4 |
| Judo | Blind Tennis | Showdown |
| TOTAL |
| 10 |

Testing Pool

On 2024 we had the follow statistics for RTP and TP, covering all the Continents:

|  |
| --- |
| Testing Pool  |
| RTP |
| Judo | Football | Goalball | Powerlifting |
| 6 | 0 | 0 | 3 |
| TP |
| Judo | Football | Goalball | Powerlifting |
| 6 | 3 (team) | 3 (team) | 3 |

\*1 ADVR: the athlete missed to fill the Whereabouts 2 times and missed a test

Education in 2024

**In-Person**

* Seminars on Goalball and Judo events for Aa and ASP\*
* Booth in Judo Events

**Online**

* Social Media Information
* Website in Compliance with WADA requeriments
* Monthly Seminars (7 in total) about the 11 WADA Education Mandatory Subjects (English)
* Anti-Doping App (English)

\*Aa and ASP – Athletes and Athlete Support Personal

**Anti-Doping Department**